Newswire (Published: Tuesday, November 17, 2020, Received: Tuesday, November 17, 2020, 5:03:50 PM CST)

Word Count: 608

2020 NOV 17 (NewsRx) -- By a News Reporter-Staff News Editor at Cancer Daily -- Investigators publish new report on prostate cancer. According to news reporting originating from Washington, District of Columbia, by NewsRx correspondents, research stated, “Stereotactic body radiation therapy (SBRT) is a safe and effective treatment option for patients with low to intermediate risk prostate cancer (1). SBRT results in very low PSA nadirs secondary to the delivery of high biologically effective doses. Studies reporting on the diagnosis, confirmation, and management of salvageable isolated local failures (ILF) are limited.”

Financial supporters for this research include National Institute on Minority Health and Health Disparities.

The news journalists obtained a quote from the research from Georgetown University Hospital: “This study aims to determine the incidence and management approach of ILF after SBRT in a large single institution cohort. All patients with low or intermediate risk localized prostate cancer treated with SBRT at Georgetown University Hospital were eligible for this study. Treatment was delivered using robotic SBRT with doses of 35-36.25 Gy in five fractions. ILF were diagnosed using multiparametric MRI and/or biopsy prompted by rising PSA levels after achieving long-term nadir. Patient’s characteristics were extracted from a prospective institutional quality of life trial (IRB 2009-510). Type of salvage therapy and post-salvage PSA were determined on subsequent follow-up and chart review. Between December 2008 to August 2018, 998 men with low to intermediate risk prostate cancer were eligible for inclusion in this analysis. Twenty-four patients (low risk, n = 5; intermediate risk, n = 19) were found to have ILF within the prostate on either MRI (n = 19) and/or biopsy (n = 20). Median pre-treatment PSA was 7.55 ng/ml. Median time to diagnosis of ILF was 72 months (24-110 months) with median PSA at the time of ILF of 2.8 ng/ml (0.7-33 ng/ml). Median PSA doubling time was 17 months (5-47 months). Thirteen patients with biopsy proven ILF proceeded with salvage therapy (cryotherapy n = 12, HIFU n = 1). Of 12 patients who underwent cryotherapy, 7 had a post-treatment PSA of <0.1 ng/ml. One patient experienced a urethral-cutaneous fistula (grade 3 toxicity). The incidence of isolated local recurrence is rare in our cohort. Diagnosis and management of isolated local failures post-SBRT continues to evolve. Our report highlights the importance of early utilization of MRI and confirmatory biopsy at relatively low PSA levels and long PSA doubling time (1).”

According to the news reporters, the research concluded: “Additionally, undetectable PSA levels after salvage therapy supports the role of early treatment in ILF (1). Further research is needed to determine appropriate patient selection and salvage modality in this population.”

For more information on this research see: Management of Isolated Local Failures Following Stereotactic Body Radiation Therapy for Low to Intermediate Risk Prostate Cancer. Frontiers in Oncology, 2020,10. (Frontiers in Oncology - http://www.frontiersin.org/oncology). The publisher for Frontiers in Oncology is Frontiers Media S.A.

A free version of this journal article is available at https://doi.org/10.3389/fonc.2020.551491.

Our news editors report that additional information may be obtained by contacting Nima Aghdam, Department of Radiation Medicine, Georgetown University Hospital, Washington, DC, United States. Additional authors for this research include Abigail N. Pepin, Michael Creswell, Kristin Hsieh, Clayton Smith, Nicolette Drescher, Malika Danner, Marilyn Ayoob, Thomas Yung, Siyuan Lei, Deepak Kumar, Brian Timothy Collins, Jonathan W. Lischalk, Pranay Krishnan, Simeng Suy, John Lynch, Guarav Bandi, Ryan Andrew Hankins, Sean P. Collins.

(Our reports deliver fact-based news of research and discoveries from around the world.)

Companies

Georgetown University Hospital Inc.

Industries

Healthcare
      Healthcare Facilities
            Hospitals
      Medical Devices
            Medical Treatment Devices
                  Radiosurgery Devices
Manufacturing
      Medical Device Manufacturing
            Medical Devices
                  Medical Treatment Devices
                        Radiosurgery Devices

Places

North America
United States
Americas
District of Columbia
Washington
D.C.

Subjects

Science and Technology
      Scientific Research
            Medical Research
Health and Wellness
      Medical Conditions and Diseases
            Cancer
                  Prostate Cancer
            Men's Health Issues
                  Prostate Cancer
      Health Sciences
            Medical Research
      Medical Specialties and Practices
            Radiology
      Treatments and Therapies
            Radiation Therapy